Spring Bank Pharmaceuticals, Inc.

Biotechnology ResearchMassachusetts, United States11-50 Employees

We are a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins implicated in various disease states. Our most advanced SMNH product candidate, SB 11285, is an intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist being developed for the treatment of certain cancers. We are developing a STING pathway portfolio of candidates with SB 11285, our STING antagonist compounds for the treatment of a broad range of inflammatory diseases and our STING agonist ADC program for potential oncology applications.

Sign up for free to view info

Email Format Employee directory